Endocrine Abstracts

Aim: Metabolic syndrome rates have been studied especially in adrenal gland secreting cortisol and studies on nonfunctional adenomas are limited. In this study, we investigated metabolic parameters and metabolic syndrome frequency in non-functional adrenal adenomas (NFA).

Materials and methods: In our study, 55 patients (15 men (27.3%), 40 women (72.7%) who were diagnosed incidentally, unilateral or bilateral localized, hormone-inactive, and with adenoma-compatible features in imaging studies were included in the study. Anthropometric parameters (BMI, waist circumference (WC)), clinical and biochemical blood indices were evaluated. As exclusion criteria; 1) <18 years old patients, 2) Pregnancy, 3) Alcoholism /substance use disorders, 4) Liver/kidney failure (Child B and C, creatine clearance <60 ml/min) 5) Glucose and weight gaining medical treatment or steroid use, 6) Acromegaly, uncontrolled hypo/hyperthyroidism, causes of secondary obesity, 7) Severe neuropsychiatric diseases, 8) Severe disease in case of septic and organ failure, 9) Post-transplantation, 10) Malignancy.

Results: The mean age of patients 53.62±8.1 years old, mean body mass index (BMI) 31.42±5.9 kg/m², body weight 83.5±6.15 kg was found. In the laboratory examination; glucose: 101.95±16.9 mg/dl; insulin 9.3±7.63 uU/ml; HOMA index 2.34±1.8, HbA1c 5.8% 0.72, LDL-cholesterol 136.2±34.5 mg/dl; triglyceride 132.5±51.2 mg/dl; HDL-cholesterol 50.2±10.8 mg/dl; total cholesterol 212.8±39.5 mg/dl; uric acid 5.12±1.01 mg/dl was observed. Hyperuricemia was observed in 14.5% (n=8) of the patients. The adenoma size was 17.11±7.61 mm and It was observed that 29.1% (n=16) of the adenomas were localized in the right (n=16), 58.2% (n=32) in the left and 10.9%(n=6) in the bilateral. 25.5% (n=14) of the patients had diabetes mellitus (DM), 32.7% (n=18) had prediabetes, 27.3% (n=15) had insulin resistance, 14.5% (n=14) had hyperlipidemia and 45.5% (n=25) had hypertension (HT) was detected. 12.7% (n=7) of the patients had normal weight, 38.2% (n=21) had overweight, 23.6% (n=8) had mild obese, 16.4% (n=9) was moderately obese and 9.1% (n=5) were morbidly obese. The rate of metabolic syndrome in our study was 41.8% (n: 23).

Conclusion: In our study, the prevalence of metabolic syndrome was found to be high in NSAID patients according to IDF 2006 diagnostic criteria. We suggest that screening for metabolic syndrome in NFAs will be useful for monitoring the function in addition to Cushing and subclinical cushing syndrome,